Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lungs Are Particularly Vulnerable in Patients with Systemic Rheumatic Disease

Lara C. Pullen, PhD  |  June 29, 2015

Systemic rheumatic diseases (SRD) affect multiple organs and are, by their very nature, heterogeneous disorders. Patients diagnosed with SRD often present for critical care management. The most common causes of intensive care unit (ICU) admission in this patient population are SRD exacerbation, treatment-related infections or toxicities.

Guillaume Dumas, MD, a critical care physician at the Saint-Louis Teaching Hospital in Paris, France, and colleagues designed a study to characterize the use of intensive care by patients with SRD. In May, they published the results of their retrospective observational study online in the journal Chest. The study’s primary endpoint was mortality, and the secondary outcome was SRD exacerbation. The investigators examined a large cohort of 363 critically ill patients with SRD who were admitted 381 times to 10 centers between Jan. 1, 2009, and Jan. 1, 2013. Data collected from the patients’ charts showed their median age to be 59 years (range = 42–70 years), and a median of three (range = 1–4) organs involved in disease. The most common SRD was systemic lupus erythematosus. SRD was newly diagnosed in approximately 10% of the cases. Patients were considered to have been admitted directly to the ICU if they were admitted from the emergency department or emergency ambulance service.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At ICU discharge, patients were retrospectively classified by the ICU physician for the cause of ICU admittance. Approximately one-third of patients were admitted to the ICU because of infection and one-third because of SRD exacerbation. In both cases, the lung was the chief target of disease. Moreover, the researchers found that acute respiratory failure was one of the most prevalent symptoms in patients admitted to the ICU, followed by shock, acute kidney injury and sepsis. Community-acquired infections and non-opportunistic infections were more common than hospital-acquired or opportunistic infections. Patients who were newly diagnosed with SRD during their ICU stay were most often placed in the ICU as a result of SRD exacerbation. The most common causes of readmissions were infection and SRD exacerbation.

Upon ICU admittance, patients had a mean Sequential Organ Failure Assessment (SOFA) score of 5. Approximately half the patients required mechanical ventilators, one-third required vasopressors, and one-third required renal replacement therapy. In 7.4% of the cases, urgent surgery (e.g., cardiac, gastrointestinal or neurological/soft tissue) was required. Approximately one-third of patients had immunosuppressive treatment initiated in the ICU. The median length of stay in the ICU was six days (range = 3–12 days).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The cohort had an overall crude mortality rate of 21%. Factors associated with mortality included shock, SOFA score on Day 1 and direct admission. Comorbidities and specific SRD characteristics were not associated with survival. The investigators found that direct admission to the ICU was, however, associated with significantly reduced mortality, and the authors concluded their paper by suggesting that patients with SRD may have improved outcomes if they are admitted directly to the ICU.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

  1. Dumas G, Géri G, Montlahuc C, et al. Outcomes in critically ill patients with systemic rheumatic disease: A multicenter study. Chest. 21 May 2015. doi:10.1378/chest.14-3098

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:critical care managementInfectionlungrheumatologySystemic Rheumatic Diseases

Related Articles

    Using Ultrasound to Diagnose Carpal Tunnel Syndrome

    April 26, 2018

    Note: Updated May 2, 2018, to correct a link in the reference section. The error was introduced in editing. A 44-year-old Caucasian woman presented to the outpatient rheumatology clinic that had followed her for several years for rheumatoid arthritis. She was compliant with her regimen of hydroxychloroquine, etanercept and salsalate. Her chief complaint was worsening…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Jarun Ontakrai / shutterstock.com Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and…

    How to Manage Critical Illness in Patients with Autoimmune Disease

    February 2, 2022

    Patients in intensive care may experience dangerous manifestations of rheumatic disease, such as digital ischemia, multi-system organ failure and more. In a session at ACR Convergence 2021, experts addressed how to manage and treat these critically ill patients.

    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    April 15, 2019

    KENARY820/SHUTTERSTOCK.COM Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences